The health burden of cancer is increasing in China, with more than 1· 6 million people being
diagnosed and 1· 2 million people dying of the disease each year. As in most other …

There is a need for anticancer agents with novel mechanisms of action. Recently identified
molecular targets for new anticancer agents include inducers of cell differentiation, cell cycle …

BACKGROUND A single‐institution review of clinical presentation, treatment, and outcome
of male breast carcinoma was conducted. METHODS Data obtained by chart review of 229 …

Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …

Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy—but not tamoxifen therapy of longer duration—prolongs disease-free and overall …

Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA. 17 trial, which was designed to determine whether …

Background Tamoxifen and raloxifene have limited patient acceptance for primary
prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers …

The practice of cancer medicine has changed dramatically in the past four decades, as
curative treatments have been identified for a number of previously fatal malignancies such …

Background Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or
after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast …

Non-communicable diseases, including cancer, are overtaking infectious disease as the
leading health-care threat in middle-income and low-income countries. Latin American and …